Dementia with Lewy Bodies
1998; Wiley; Volume: 46; Issue: 11 Linguagem: Inglês
10.1111/j.1532-5415.1998.tb06016.x
ISSN1532-5415
AutoresEstrella Gómez‐Tortosa, Aubrey O. Ingraham, Michael C. Irizarry, Bradley T. Hyman,
Tópico(s)Ginkgo biloba and Cashew Applications
ResumoJournal of the American Geriatrics SocietyVolume 46, Issue 11 p. 1449-1458 Dementia with Lewy Bodies Estrella Gómez-Tortosa MD, PhD, Estrella Gómez-Tortosa MD, PhD Alzheimer's Disease Research Unit, Massachusetts General Hospital East, Charlestown, Massachusetts. E. Gómez-Tortosa was supported by a grant from Fundación Conchita Rábago, Madrid, Spain.Search for more papers by this authorAubrey O. Ingraham BA, Aubrey O. Ingraham BA Alzheimer's Disease Research Unit, Massachusetts General Hospital East, Charlestown, Massachusetts.Search for more papers by this authorMichael C. Irizarry MD, Michael C. Irizarry MD Alzheimer's Disease Research Unit, Massachusetts General Hospital East, Charlestown, Massachusetts.Search for more papers by this authorBradley T. Hyman MD, PhD, Corresponding Author Bradley T. Hyman MD, PhD Alzheimer's Disease Research Unit, Massachusetts General Hospital East, Charlestown, Massachusetts.Alzheimer's Disease Research Unit, Massachusetts General Hospital East, 149 13th Street, Room 6405, Charlestown, MA 02119.Search for more papers by this author Estrella Gómez-Tortosa MD, PhD, Estrella Gómez-Tortosa MD, PhD Alzheimer's Disease Research Unit, Massachusetts General Hospital East, Charlestown, Massachusetts. E. Gómez-Tortosa was supported by a grant from Fundación Conchita Rábago, Madrid, Spain.Search for more papers by this authorAubrey O. Ingraham BA, Aubrey O. Ingraham BA Alzheimer's Disease Research Unit, Massachusetts General Hospital East, Charlestown, Massachusetts.Search for more papers by this authorMichael C. Irizarry MD, Michael C. Irizarry MD Alzheimer's Disease Research Unit, Massachusetts General Hospital East, Charlestown, Massachusetts.Search for more papers by this authorBradley T. Hyman MD, PhD, Corresponding Author Bradley T. Hyman MD, PhD Alzheimer's Disease Research Unit, Massachusetts General Hospital East, Charlestown, Massachusetts.Alzheimer's Disease Research Unit, Massachusetts General Hospital East, 149 13th Street, Room 6405, Charlestown, MA 02119.Search for more papers by this author First published: 27 April 2015 https://doi.org/10.1111/j.1532-5415.1998.tb06016.xCitations: 22 This article is one in a series on Geriatric Bioscience, Jesse Roth, MD, Series Editor. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Okazaki H., Upton I., Aronson S.. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neurol Neurosurg Psychiatry 1961; 20: 237–244. PubMedWeb of Science®Google Scholar 2 Hughes AJ. Clinicopathological aspects of Parkinson's disease. Eur Neurol 1997; 38(suppl 2): 13–20. 10.1159/000113471 PubMedWeb of Science®Google Scholar 3 Kosaka K., Matsushita M., Oyanagi S. et al. A clinicopathological study of "Lewy body disease." Psychiatr Neurol Jpn 1980; 82: 292–311. CASPubMedGoogle Scholar 4 Perry R., Jaros E., Irving D. et al. What is the neuropathological basis of dementia associated with Lewy bodies? In: R. Perry, I. McKeith, E. Perry, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 212–223. 10.1017/CBO9780511601187.022 Google Scholar 5 Joachim C., Morris J., Selkoe D.. Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases. Ann Neurol 1988; 24: 50–56. 10.1002/ana.410240110 CASPubMedWeb of Science®Google Scholar 6 Byrne E., Lennox G., Lowe J., Godwin-Austen R.. Diffuse Lewy body disease: Clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989; 52: 709–717. 10.1136/jnnp.52.6.709 CASPubMedWeb of Science®Google Scholar 7 Perry R., Irving D., Blessed G. et al. Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990; 95: 119–139. 10.1016/0022-510X(90)90236-G CASPubMedWeb of Science®Google Scholar 8 Hansen L., Salmon D., Galasko D. et al. The Lewy body variant of Alzheimer's disease: A clinical and pathological entity. Neurology 1990; 40: 1–8. 10.1212/WNL.40.1.1 CASPubMedWeb of Science®Google Scholar 9 Hansen L., Masliah E., Galasko D., Terry R.. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993; 52: 648–654. 10.1097/00005072-199311000-00012 CASPubMedWeb of Science®Google Scholar 10 Galasko D., Hansen L., Katzman R. et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994; 51: 888–895. 10.1001/archneur.1994.00540210060013 CASPubMedWeb of Science®Google Scholar 11 Kosaka K.. Dementia and neuropathology in Lewy body disease. Adv Neurol 1993; 60: 456–463. CASPubMedWeb of Science®Google Scholar 12 Burns A.. Clinical features of patients with Alzheimer's disease and Lewy bodies. In: R. Perry, I. McKeith, E. Perry, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 46–56. 10.1017/CBO9780511601187.008 Google Scholar 13 Olichney J., Hofstetter C., Salmon D. et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology (Abstract) 1997; 48: 140. Google Scholar 14 Salmon DP, Galasko D., Hansen LA et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996; 31: 148–165. 10.1006/brcg.1996.0039 CASPubMedWeb of Science®Google Scholar 15 Gibb W., Esiri M., Lees A.. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987; 110: 1131–1153. 10.1093/brain/110.5.1131 PubMedWeb of Science®Google Scholar 16 Galasko D., Katzman R., Salmon DP, Hansen L.. Clinical and neuropathological findings in Lewy body dementias. Brain Cogn 1996; 31: 166–175. 10.1006/brcg.1996.0040 CASPubMedWeb of Science®Google Scholar 17 Louis ED, Klatka LA, Liu Y., Fahn S.. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997; 48: 376–380. 10.1212/WNL.48.2.376 CASPubMedWeb of Science®Google Scholar 18 Ballard C., Lowery K., Harrison R., McKeith I.. Noncognitive symptoms in Lewy body dementia. In: R. Perry, I. McKeith, E. Perry, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 67–84. 10.1017/CBO9780511601187.010 Web of Science®Google Scholar 19 McShane R., Keene J., Gedling K., Hope T.. Hallucinations, cortical Lewy body pathology, cognitive function and neuroleptic use in dementia. In: R. Perry, I. McKeith, E. Perry, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 85–98. 10.1017/CBO9780511601187.011 Google Scholar 20 Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: A clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology 1996; 47: 1148–1152. 10.1212/WNL.47.5.1148 CASPubMedWeb of Science®Google Scholar 21 Kosaka K.. Diffuse Lewy body disease in Japan. J Neurol 1990; 237: 197–204. 10.1007/BF00314594 CASPubMedWeb of Science®Google Scholar 22 McKeith I., Galasko D., Kosaka K. et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–1124. 10.1212/WNL.47.5.1113 CASPubMedWeb of Science®Google Scholar 23 Byrne E., Lennox G., Godwin-Austen R. et al. Diagnostic criteria for dementia associated with cortical Lewy bodies. Dementia 1991; 2: 283–284. Google Scholar 24 McKeith I., Perry R., Fairbairn A. et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992; 22: 911–922. 10.1017/S0033291700038484 CASPubMedWeb of Science®Google Scholar 25 Burkhardt C., Filley C., Kleinschmidt-DeMasters B. et al. Diffuse Lewy body disease and progressive dementia. Neurology 1988; 38: 1520–1528. 10.1212/WNL.38.10.1520 CASPubMedWeb of Science®Google Scholar 26 Yamamoto T., Imai T.. A case of diffuse Lewy body and Alzheimer's disease with periodic synchronous discharges. J Neuropathol Exp Neurol 1988; 47: 536–548. 10.1097/00005072-198809000-00005 CASPubMedWeb of Science®Google Scholar 27 Crystal H., Dickson D., Lizardi J. et al. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990; 40: 1523–1528. 10.1212/WNL.40.10.1523 CASPubMedWeb of Science®Google Scholar 28 Albin R., Minoshima S., D'Amato C. et al. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996; 47: 462–466. 10.1212/WNL.47.2.462 CASPubMedWeb of Science®Google Scholar 29 Ishii K., Imamura T., Sasaki M. et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998; 51: 125–130. 10.1212/WNL.51.1.125 CASPubMedWeb of Science®Google Scholar 30 Donnemiller E., Heilmann J., Wenning GK et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 1231-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997; 24: 320–325. 10.1007/BF01728771 CASPubMedWeb of Science®Google Scholar 31 Walker Z., Costa D., Janssen A. et al. Dementia with Lewy bodies: A study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997; 24: 609–614. 10.1007/BF00841397 CASPubMedWeb of Science®Google Scholar 32 Spellman G.. Report of familial cases of parkinsonism. JAMA 1962; 179: 372–374. 10.1001/jama.1962.03050050062014 CASPubMedWeb of Science®Google Scholar 33 Muenter M., Howard FJ, Okazaki H. et al. A familial parkinson-dementia syndrome. Neurology (Suppl 1) 1986; 36: 115. PubMedGoogle Scholar 34 Inose T., Miyakawa M., Miyakawa K. et al. Clinical and neuropathological study of a familial case of juvenile parkinsonism. Jpn J Psychiatry Neurol 1989; 42: 265–276. Web of Science®Google Scholar 35 Golbe L., Lazarini A., Schwartz K. et al. Autosomal dominant parkinsonism with benign course and typical Lewy-body pathology. Neurology 1993; 43: 2222–2227. CASPubMedGoogle Scholar 36 Waters C., Miller C.. Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 1994; 35: 59–64. 10.1002/ana.410350110 CASPubMedWeb of Science®Google Scholar 37 Denson MA, Wszolek ZK, Pfeiffer RF et al. Familial parkinsonism, dementia, and Lewy body disease: Study of family G. Ann Neurol 1997; 42: 638–643. 10.1002/ana.410420415 CASPubMedWeb of Science®Google Scholar 38 Ishikawa A., Takahashi H., Tanaka H. et al. Clinical features of familial diffuse Lewy body disease. Eur Neurol 1997; 38(suppl l): 34–38. 10.1159/000113459 PubMedWeb of Science®Google Scholar 39 Marder K., Flood P., Cote L., Mayeux R.. A pilot study of risk factors for dementia in Parkinson's disease. Mov Disord 1990; 5: 156–161. 10.1002/mds.870050212 CASPubMedWeb of Science®Google Scholar 40 Hofman A., Schulte W., Tanja T. et al. History of dementia and Parkinson's disease in lst-degree relative of patients with Alzheimer's disease. Neurology 1989; 39: 1589–1592. 10.1212/WNL.39.12.1589 CASPubMedWeb of Science®Google Scholar 41 Majoor-Krakauer D., Ottman R., Johnson W., Rowland L.. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: Evidence of shared genetic susceptibility. Neurology 1994; 44: 1872–1877. 10.1212/WNL.44.10.1872 CASPubMedWeb of Science®Google Scholar 42 Iwai A., Masliah E., Yoshimoto M. et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995; 14: 467–475. 10.1016/0896-6273(95)90302-X CASPubMedWeb of Science®Google Scholar 43 Polymeropoulos MH, Lavedan C., Leroy E. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–2047. 10.1126/science.276.5321.2045 CASPubMedWeb of Science®Google Scholar 44 Munoz E., Oliva R., Obach V. et al. Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients. Neurosci Lett 1997; 235: 57–60. 10.1016/S0304-3940(97)00710-6 CASPubMedWeb of Science®Google Scholar 45 The French Parkinson's Disease Genetics Study Group. Alpha-synuclein gene and Parkinson's disease. Science 1998; 279: 1116–1117. 10.1126/science.279.5354.1113g PubMedGoogle Scholar 46 Chan P., Tanner CM, Jiang X., Langston JW. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology 1998; 50: 513–514. 10.1212/WNL.50.2.513 CASPubMedWeb of Science®Google Scholar 47 Farrer M., Vrieze Wavrant-De F., Crook R. et al. Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann Neurol 1998; 43: 394–397. 10.1002/ana.410430320 CASPubMedWeb of Science®Google Scholar 48 Kruger R., Kuhn W., Muller T. et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106–108. 10.1038/ng0298-106 CASPubMedWeb of Science®Google Scholar 49 Spillantini M., Schmidt M., Lee V. et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839–840. 10.1002/ana.67 CASPubMedWeb of Science®Google Scholar 50 Irizarry M., Growdon W., Gomez-Isla T. et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998; 57: 334–337. 10.1097/00005072-199804000-00005 CASPubMedWeb of Science®Google Scholar 51 Takeda A., Mallory M., Sundsmo M. et al. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol 1998; 152: 367–372. CASPubMedWeb of Science®Google Scholar 52 Irizarry M., Kim T., McNamara M. et al. Characterization of the precursor protein of the non-A βcomponent of senile plaques (NACP) in the human central nervous system. J Neuropathol Exp Neurol 1996; 55: 889–895. 10.1097/00005072-199608000-00004 CASPubMedWeb of Science®Google Scholar 53 Masliah E., Iwai A., Mallory M. et al. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Parkinson's disease. Am J Pathol 1996; 148: 201–210. CASPubMedWeb of Science®Google Scholar 54 Armstrong M., Daly A., Cholerton S. et al. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339: 1017–1018. 10.1016/0140-6736(92)90537-D CASPubMedWeb of Science®Google Scholar 55 Smith C., Gough A., Leigh P. et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375–1377. 10.1016/0140-6736(92)91196-F CASPubMedWeb of Science®Google Scholar 56 Kurth M., Kurth J.. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993; 48: 166–168. 10.1002/ajmg.1320480311 PubMedWeb of Science®Google Scholar 57 McCann SJ, Pond SM, James KM, Le Couteur DG. The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: A case-control study and meta-analysis. J Neurol Sci 1997; 153: 50–53. 10.1016/S0022-510X(97)00179-2 CASPubMedWeb of Science®Google Scholar 58 Agundez JA, Jimenez-Jimenez FJ, Luengo A. et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995; 57: 291–298. 10.1016/0009-9236(95)90154-X CASPubMedWeb of Science®Google Scholar 59 Saitoh T., Xia Y., Chen X. et al. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol 1995; 37: 110–112. 10.1002/ana.410370120 CASPubMedWeb of Science®Google Scholar 60 Plante-Bordeneuve V., Davis M., Maraganore D. et al. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 911–913. 10.1136/jnnp.57.8.911 CASPubMedWeb of Science®Google Scholar 61 Gasser T., Muller-Myhsok B., Supala A. et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 518–520. 10.1136/jnnp.61.5.518 CASPubMedWeb of Science®Google Scholar 62 Diederich N., Hilger C., Goetz CG et al. Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996; 40: 463–465. 10.1002/ana.410400319 CASPubMedWeb of Science®Google Scholar 63 Sandy MS, Armstrong M., Tanner CM et al. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 1996; 47: 225–230. 10.1212/WNL.47.1.225 CASPubMedWeb of Science®Google Scholar 64 Tsuneoka Y., Matsuo Y., Ichikawa Y., Watanabe Y.. Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease. Metabolism 1998; 47: 94–96. 10.1016/S0026-0495(98)90199-8 CASPubMedWeb of Science®Google Scholar 65 Saitoh T., Katzman R.. Genetic correlations in Lewy body disease. In: R. Perry, I. McKeith, E. Perry, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 336–349. 10.1017/CBO9780511601187.032 Google Scholar 66 Gasser T., Muller-Myhsok B., Wszolek Z. et al. A susceptibility locus for Parkinson's disease maps to chromosome 2pl3. Nat Genet 1998; 18: 262–265. 10.1038/ng0398-262 CASPubMedWeb of Science®Google Scholar 67 Kitada T., Asakawa S., Hattori N. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 329: 605–608. Google Scholar 68 Saunders A., Strittmatter W., Schmechel D. et al. Association of apolipoprotein E allele epsilon4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467–1472. 10.1212/WNL.43.8.1467 CASPubMedWeb of Science®Google Scholar 69 Rebeck WG, Reiter JS, Strickland DK, Hyman B. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 1993; 11: 575–580. 10.1016/0896-6273(93)90070-8 CASPubMedWeb of Science®Google Scholar 70 Pickering-Brown S., Mann D., Bourke J. et al. Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other β-amyloidforming diseases. Lancet (Letter) 1994; 343: 1155. 10.1016/S0140-6736(94)90257-7 CASPubMedWeb of Science®Google Scholar 71 Benjamin R., Leake A., Ince PG et al. Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. Neurodegeneration 1995; 4: 443–448. 10.1006/neur.1995.0053 CASPubMedWeb of Science®Google Scholar 72 Hansen L., Galasko D., Samuel W. et al. Apolipoprotein-E epsilon-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. Neurosci Lett 1994; 182: 63–65. 10.1016/0304-3940(94)90206-2 CASPubMedWeb of Science®Google Scholar 73 Harrington C., Louwagie J., Rossau R. et al. Influence of the apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types: Significance for etiological theories of Alzheimer's disease. Am J Pathol 1994; 145: 1472–1482. CASPubMedWeb of Science®Google Scholar 74 Lippa CF, Smith TW, Saunders AM et al. Apolipoprotein E genotype and Lewy body disease. Neurology 1995; 45: 97–103. 10.1212/WNL.45.1.97 CASPubMedWeb of Science®Google Scholar 75 Galasko D., Saitoh Y., Xia Y. et al. The apolipoprotein F. allele epsilon 4 is over represented in patients with the Lewy body variant of Alzheimer's disease. Neurology 1994; 44: 1950–1951. 10.1212/WNL.44.10.1950 CASPubMedWeb of Science®Google Scholar 76 Dickson DW, Crystal H., Davies P., Hardy J.. Cytoskeletal and Alzheimer-type pathology in Lewy body disease. In: R. Perry, I. McKeith, E. Perry, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 224–237. 10.1017/CBO9780511601187.023 Web of Science®Google Scholar 77 Koller WC, Glatt SL, Hubble JP et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995; 37: 242–245. 10.1002/ana.410370215 CASPubMedWeb of Science®Google Scholar 78 Kurth J., Kurth M., Poduslo S., Schwankhaus J.. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993; 33: 368–372. 10.1002/ana.410330406 CASPubMedWeb of Science®Google Scholar 79 Hotamisligil G., Girmen A., Fink J. et al. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov Disord 1994; 9: 305–310. 10.1002/mds.870090304 CASPubMedWeb of Science®Google Scholar 80 Ho SL, Kapadi AL, Ramsden DB, Williams AC. An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol 1995; 37: 403–405. 10.1002/ana.410370318 CASPubMedWeb of Science®Google Scholar 81 Plante-Bordencuve V., Taussig D., Thomas F. et al. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of 3 DRD2 allele. Neurology 1997; 48: 1589–1593. 10.1212/WNL.48.6.1589 PubMedWeb of Science®Google Scholar 82 Hoda F., Nicholl D., Bennett P. et al. No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Biochem Biophys Res Commun 1996; 228: 780–784. 10.1006/bbrc.1996.1731 CASPubMedWeb of Science®Google Scholar 83 Syvanen AC, Tilgmann C., Rinne J., Ulmanen I.. Genetic polymorphism of catcchol-O-methyltransferase (COMT): Correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 1997; 7: 65–71. 10.1097/00008571-199702000-00009 CASPubMedWeb of Science®Google Scholar 84 Xie T., Ho SL, Li LS, Ma OC. G/A 1947 polymorphism in carechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord 1997; 12: 426–427. 10.1002/mds.870120325 CASPubMedWeb of Science®Google Scholar 85 Kunugi H., Nanko S., Ueki A. et al. High and low activity alleles of catechol-O-methyltransfcrase gene: Ethnic difference and possible association with Parkinson's disease. Neurosci Lett 1997; 221: 202–204. 10.1016/S0304-3940(96)13289-4 CASPubMedWeb of Science®Google Scholar 86 Plante-Bordeneuve V., Davis M., Maraganore D. et al. Tyrosine hydroxylase gene polymorphism in familial and sporadic Parkinson's disease. Mov Disord 1994; 9: 337–339. 10.1002/mds.870090312 CASPubMedWeb of Science®Google Scholar 87 Ludecke B., Knappskog PM, Clayton PT et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996; 5: 1023–1028. 10.1093/hmg/5.7.1023 CASPubMedWeb of Science®Google Scholar 88 Higuchi S., Muramatsu T., Arai H. et al. Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease. J Neural Transm 1995; 10: 107–113. 10.1007/BF02251226 CASPubMedWeb of Science®Google Scholar 89 Kobayashi T., Marsumine H., Matuda S., Mizuno Y.. Association between the gene encoding the E2 subunit of the alpha-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann Neurol 1998; 43: 120–123. 10.1002/ana.410430121 CASPubMedWeb of Science®Google Scholar 90 Kosaka K., Iseki E.. Dementia with Lewy bodies. Curr Opin Neurol 1996; 9: 271–275. 10.1097/00019052-199608000-00005 CASPubMedWeb of Science®Google Scholar 91 Mezey E., Dehejia A., Harta G. et al. Alpha synuclein in neurodegenerative disorders: murderer or accomplice? Nat Med 1998; 4: 755–757. 10.1038/nm0798-755 CASPubMedWeb of Science®Google Scholar 92 Dale G., Probst A., Luthert P. et al. Relationships between Lewy bodies and pale bodies in Parkinson's disease. Acta Neuropathol (Berl) 1992; 83: 525–529. 10.1007/BF00310030 CASPubMedWeb of Science®Google Scholar 93 Rezaie P., Cairns NJ, Chadwick A., Lantos PL. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci Lett 1996; 212: 111–114. 10.1016/0304-3940(96)12775-0 CASPubMedWeb of Science®Google Scholar 94 Iseki E., Odawara T., Kosaka et al. A quantitative study of Lewy bodies and senile changes in the amygdala in diffuse Lewy body disease. Neuropathol Appl Neurobiol 1995; 15: 112–116. 10.1111/j.1440-1789.1995.tb00252.x Google Scholar 95 Wakabayashi K., Hansen LA, Masliah E.. Cortical Lewy body-containing neurons are pyramidal cells: Laser confocal imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. Acta Neuropathol (Berl) 1995; 89: 404–408. 10.1007/BF00307643 CASPubMedWeb of Science®Google Scholar 96 Goldman J., Yna S., Chiu F., Peress N.. Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 1983; 221: 1082–1084. 10.1126/science.6308771 CASPubMedWeb of Science®Google Scholar 97 Forno L., Sternberger L., Sternberger N. et al. Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments. Neurosci Lett 1986; 64: 253–258. 10.1016/0304-3940(86)90337-X CASPubMedWeb of Science®Google Scholar 98 Galloway P., Grundkc-Iqbal I., Iqbal K., Perry G.. Lewy bodies contain epitopes both shared and distinct from Alzheimer's neurofibrillary tangles. J Neuropathol Exp Neurol 1988; 47: 654–663. 10.1097/00005072-198811000-00008 CASPubMedWeb of Science®Google Scholar 99 Galloway P., Mulvihill P., Perry G.. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 1992; 140: 809–822. CASPubMedWeb of Science®Google Scholar 100 Bancher C., Lassmann H., Budka H. et al. An antigenic profile of Lewy bodies: Immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol 1989; 48: 81–93. 10.1097/00005072-198901000-00007 PubMedWeb of Science®Google Scholar 101 Schmidt M., Murray J., Lee V-Y et al. Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 1991; 139: 53–65. CASPubMedWeb of Science®Google Scholar 102 Hill W., Lee V-Y, Hurtig H. et al. Epitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson's disease Lewy bodies. J Comp Neurol 1991; 309: 150–160. 10.1002/cne.903090111 CASPubMedWeb of Science®Google Scholar 103 Pollanen M., Bergeron C., Weyer L.. Detergent-insoluble cortical Lewy body fibrils share epitopes with neurofilament and tau. J Neurochem 1992; 58: 1953–1956. 10.1111/j.1471-4159.1992.tb10074.x CASPubMedWeb of Science®Google Scholar 104 Smith MC, Mallory M., Hansen LA et al. Fragmentation of the neuronal cytoskeleton in the Lewy body variant of Alzheimer's disease. Neuroreport 1995; 6: 673–676. 10.1097/00001756-199503000-00022 CASPubMedWeb of Science®Google Scholar 105 Galvin JE, Lee VM, Baba M. et al. Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit. Ann Neurol 1997; 42: 595–603. 10.1002/ana.410420410 CASPubMedWeb of Science®Google Scholar 106 Kuzuhara S., Mori H., Izumiyama N. et al. Lewy bodies are ubiquitinated: A light and electron microscopic immunocytochemical study. Acta Neuropathol (Berl) 1988; 75: 345–353. 10.1007/BF00687787 CASPubMedWeb of Science®Google Scholar 107 Gai WP, Blumbergs PC, Blessing WW. Microtubule-associated protein 5 is a component of Lewy bodies and Lewy neurites in the brainstem and fore-brain regions affected in Parkinson's disease. Acta Neuropathol (Berl) 1996; 91: 78–81. 10.1007/s004010050395 CASPubMedGoogle Scholar 108 Arai H., Lee V-Y, Hill W. et al. Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease. Brain Res 1992; 585: 386–390. 10.1016/0006-8993(92)91242-7 CASPubMedWeb of Science®Google Scholar 109 Trojanowski JQ, Lee VM. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: Implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998; 55: 151–152. 10.1001/archneur.55.2.151 CASPubMedWeb of Science®Google Scholar 110 Lwatsubo T., Nakano I., Fukunaga K., Miyamoto E.. Ca2+/calmodulin-dependent protein kinase II immunoreactivity in Lewy bodies. Acta Neuropathol (Berl) 1991; 82: 159–163. 10.1007/BF00294440 Google Scholar 111 Brion JP, Couck AM. Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am J Pathol 1995; 147: 1465–1476. CASPubMedWeb of Science®Google Scholar 112 Nishimura M., Tomimoto H., Suenaga T. et al. Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson's disease brains. Brain Res 1994; 634: 339–344. 10.1016/0006-8993(94)91940-2 CASPubMedWeb of Science®Google Scholar 113 Lowe J., Blanchard A., Morrell K. et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle and Mallory's bodies in alcoholic liver disease. J Pathol 1988; 155: 9–15. 10.1002/path.1711550105 PubMedWeb of Science®Google Scholar 114 Manetto V., Perry G., Tabaton M. et al. Ubiquitin is associated with abnormal cytoplasmic filaments characteristic of neurodegenerative disease. Proc Natl Acad Sci U S A 1988; 85: 4501–4505. 10.1073/pnas.85.12.4501 CASPubMedWeb of Science®Google Scholar 115 Lennox G., Lowe J., Morrell K. et al. Antiubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989; 52: 67–71. 10.1136/jnnp.52.1.67 CASPubMedWeb of Science®Google Scholar 116 Love S., Nicoli A.. Comparison of modified Bielschowsky silver impregnation and anti-ubiquitin immunostainig of cortical and nigral Lewy bodies. Neuropathol Appl Neurobiol 1992; 18: 585–592. 10.1111/j.1365-2990.1992.tb00830.x CASPubMedWeb of Science®Google Scholar 117 Lowe J., McDermott H., Landon M. et al. Ubiquitin carboxy-terminal hydrolase (PGP9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative disease. J Pathol 1990; 161: 153–160. 10.1002/path.1711610210 CASPubMedWeb of Science®Google Scholar 118 Lowe J., Landon M., Pike I. et al. Dementia with β-amyloid deposition: Involvement of αB-crystallin supports two main diseases. Lancet 1990; 336: 515–516. 10.1016/0140-6736(90)92075-S CASPubMedWeb of Science®Google Scholar 119 Lowe J., McDermott H., Pike L. et al. αB crystallin expression in nonlenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease. J Pathol 1992; 166: 61–68. 10.1002/path.1711660110 CASPubMedWeb of Science®Google Scholar 120 Kwak S., Masaki T., Ishiura S., Sugita H.. Multicatalytic proteinase is present in Lewy bodies and neurofibrillary tangles in diffuse Lewy body disease brains. Neurosci Lett 1991; 128: 21–24. 10.1016/0304-3940(91)90751-E CASPubMedWeb of Science®Google Scholar 121 Ito H., Ii K., Hirano A., Dickson D.. Immunohistochemical identification of the proteasome in ubiquitin reactive abnormal structures of the nervous system. J Neuropathol Exp Neurol (Abstract) 1991; 50: 360. Google Scholar 122 Yamada T., McGeer P., McGeer E.. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol (Berl) 1992; 84: 100–104. 10.1007/BF00427222 CASPubMedWeb of Science®Google Scholar 123 Papolla M., Adorn A., Chou S.. Serum protein antigens with Lewy bodies of Parkinson's disease. Ann Neurol (abstract) 1984; 66: 136. Google Scholar 124 Nishiyama K., Murayama S., Shimizu J. et al. Cu/Zn superoxide dismutaselike immunoreactivity is present in Lewy bodies from Parkinson's disease: A light and electron microscopic immunocytochemical study. Acta Neuropathol (Berl) 1995; 89: 471–474. 10.1007/BF00571500 CASPubMedWeb of Science®Google Scholar 125 Yamada T., McGeer P., Baimbridge K., McGeer E.. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28 k. Brain Res 1990; 526: 303–307. 10.1016/0006-8993(90)91236-A CASPubMedWeb of Science®Google Scholar 126 Pollanen M., Dickson D., Bergeron C.. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993; 52: 183–191. 10.1097/00005072-199305000-00001 CASPubMedWeb of Science®Google Scholar 127 Lowe J.. Lewy bodies. In: Neurodegenerative Diseases. Philadelphia: WB Saunders, 1994. Web of Science®Google Scholar 128 Lowe J., Mayer R., Landon M.. Pathological significance of Lewy bodies in dementia. In: R. Perry, I. McKeith, E. Perry, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 195–203. 10.1017/CBO9780511601187.020 Google Scholar 129 Bergeron C., Petrunka C., Weyer L., Pollanen MS. Altered neurofilament expression does not contribute to Lewy body formation. Am J Pathol 1996; 148: 267–272. CASPubMedWeb of Science®Google Scholar 130 Dickson D., Ruan D., Crystal H. et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light and electron microscopic immunocytochemistry of CA2–3 neurites specific to DLBD. Neurology 1991; 41: 1402–1409. 10.1212/WNL.41.9.1402 CASPubMedWeb of Science®Google Scholar 131 Braak H., Braak E., Yilmazer D. et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994; 88: 493–500. 10.1007/BF00296485 PubMedWeb of Science®Google Scholar 132 Dickson D., Schmidt M., Lee V-Y et al. Hippocampal neurites in diffuse Lewy body disease: Immunocytochemical characterization and local origin. Acta Neuropathol (Beri) 1994; 87: 269–276. 10.1007/BF00296742 CASPubMedWeb of Science®Google Scholar 133 Hansen L.. Tautological tangles in neuropathological criteria for dementias associated with Lewy bodies. In: R. Perry, I. McKeith, E. Perry, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge, UK: Cambridge University Press, 1996, pp 204–211. 10.1017/CBO9780511601187.021 Google Scholar 134 Gibb W., Mountjoy C., Mann D., Lees A.. A pathological study of the association between Lewy body disease and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1989; 52: 701–708. 10.1136/jnnp.52.6.701 CASPubMedWeb of Science®Google Scholar 135 Strong C., Anderton BH, Perry RH et al. Abnormally phosphorylated tau protein in senile dementia of Lewy body type and Alzheimer disease: Evidence that the disorders are distinct. Alzheimer Dis Assoc Disord 1995; 9: 218–222. 10.1097/00002093-199509040-00008 CASPubMedWeb of Science®Google Scholar 136 Samuel W., Crowder R., Hofstetter CR, Hansen L.. Neuritic plaques in the Lewy body variant of Alzheimer disease lack paired helical filaments. Neurosci Lett 1997; 223: 73–76. 10.1016/S0304-3940(97)13404-8 CASPubMedWeb of Science®Google Scholar 137 Masliah E., Mallory M., Hansen L. et al. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 1993; 43: 192–197. 10.1212/WNL.43.1_Part_1.192 CASPubMedWeb of Science®Google Scholar 138 Crystal H., Dickson D., Sliwinski M. et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol 1993; 34: 566–573. 10.1002/ana.410340410 PubMedWeb of Science®Google Scholar 139 Dickson D., Crystal H., Mattiace L. et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992; 13: 179–189. 10.1016/0197-4580(92)90027-U CASPubMedWeb of Science®Google Scholar 140 Gomez-Isla T., West H., Rebeck G. et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996; 39: 62–70. 10.1002/ana.410390110 CASPubMedWeb of Science®Google Scholar 141 Dickson D., Crystal H., Mattiace L. et al. Diffuse Lewy body disease: Light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (Berl) 1989; 78: 572–584. 10.1007/BF00691284 CASPubMedWeb of Science®Google Scholar 142 Dickson D., Wu E., Crystal H. et al. Alzheimer and age-related changes in diffuse Lewy body disease. In: FF Boller, Z. Kachaturian, M. Poncet, Y. Christen, eds. Heterogeneity of Alzheimer's Disease. Berlin: Springer-Verlag, 1992, pp 168–186. 10.1007/978-3-642-46776-9_17 Web of Science®Google Scholar 143 Armstrong R., Cairns N., Lantos P.. β-Amyloid (Aβ) deposition in the medial temporal lobe of patients with dementia with Lewy bodies. Neurosci Lett 1997; 227: 193–196. 10.1016/S0304-3940(97)00343-1 CASPubMedWeb of Science®Google Scholar 144 Masliah E., Mallory M., DeTeresa R. et al. Differing patterns of aberrant neuronal sprouting in Alzheimer's disease with and without Lewy bodies. Brain Res 1993; 617: 258–266. 10.1016/0006-8993(93)91093-8 CASPubMedWeb of Science®Google Scholar 145 Samuel W., Alford M., Hofstetter CR, Hansen L.. Dementia with Lewy bodies versus pure Alzheimer disease: Differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997; 56: 499–508. 10.1097/00005072-199705000-00006 CASPubMedWeb of Science®Google Scholar 146 Lippa CF, Pulaski-Salo D., Dickson DW, Smith TW. Alzheimer's disease, Lewy body disease and aging: A comparative study of the perforant pathway. J Neurol Sci 1997; 147: 161–166. 10.1016/S0022-510X(96)05321-X CASPubMedWeb of Science®Google Scholar 147 Iseki E., Li F., Kosaka K.. Close relationship between spongiform change and ubiquitin-positive granular structures in diffuse Lewy body disease. J Neurol Sci 1997; 146: 53–57. 10.1016/S0022-510X(96)00282-1 CASPubMedWeb of Science®Google Scholar 148 Hansen L., Masliah E., Terry R. et al. A neuropathological subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol (Berl) 1989; 78: 194–201. 10.1007/BF00688209 CASPubMedWeb of Science®Google Scholar 149 Sima A., Clark A., Stemberger N., Stemberger L.. Lewy body dementia without Alzheimer changes. Can J Neurol Sci 1986; 13: 490–497. 10.1017/S0317167100037185 CASPubMedWeb of Science®Google Scholar 150 Kuljis R., Martin-Vasallo P., Peress N.. Lewy bodies in tyrosine hydroxylase synthesizing neurons of the human cerebral cortex. Neurosci Lett 1989; 106: 49–54. 10.1016/0304-3940(89)90200-0 CASPubMedWeb of Science®Google Scholar 151 Perry E., Marshall E., Perry R. et al. Cholinergic and dopaminergic activities in senile dementia of the Lewy body type. Alzheimer Dis Assoc Disord 1990; 4: 87–95. 10.1097/00002093-199040200-00003 CASPubMedGoogle Scholar 152 Liu Y., Stern Y., Chun M. et al. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 1997; 41: 368–374. 10.1002/ana.410410312 CASPubMedWeb of Science®Google Scholar 153 Lennox G., Lowe J., Landon M. et al. Diffuse Lewy body disease, correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989; 52: 1236–1247. 10.1136/jnnp.52.11.1236 CASPubMedWeb of Science®Google Scholar 154 Samuel W., Galasko D., Masliah E., Hansen LA. Neocortical lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55: 44–52. 10.1097/00005072-199601000-00005 CASPubMedWeb of Science®Google Scholar Citing Literature Volume46, Issue11November 1998Pages 1449-1458 ReferencesRelatedInformation
Referência(s)